Neuren Pharmaceuticals is developing new therapies for debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. Incorporated in New Zealand and based in Melbourne, Australia, Neuren is listed on the ASX under the code NEU. 1 Neuren’s value proposition 2 Chair and CEO message 4 Operating Review 14 Board 15 Executive Team 16 Environmental, Social and Governance (ESG) 23 Directors’ Responsibilities Statement 24 Consolidated statement of Profit or Loss and Other Comprehensive Income 25 Consolidated Statement of Financial Position 26 Consolidated Statement of Changes in Equity 27 Consolidated Statement of Cash Flows 28 Notes to the Consolidated Financial Statements 48 Independent Auditor’s Report 51 Additional Information CONTENTS
RkJQdWJsaXNoZXIy MjE2NDg3